18F-PSMA 1007 PET/CT 用于疑似肾细胞癌
一例60岁男性疑似右肾细胞癌患者接受18F-FDG PET/CT与18F-PSMA 1007 PET/CT检查;
要点
- 18F-PSMA 1007 PET/CT在原发右肾肿瘤显示强烈示踪剂浓聚。
- 18F-PSMA 1007 PET/CT在所有肺结节均显示强烈示踪剂浓聚。
核心结论
- 18F-PSMA 1007 PET/CT可能为疑似肾细胞癌的评估提供术前病因、肿瘤类型组织病理学概率、分期信息及诊疗一体化潜力方面的洞见。
研究设计与样本
- 一例60岁男性疑似右肾细胞癌患者,接受18F-FDG PET/CT与18F-PSMA 1007 PET/CT扫描。
主要发现
- 与18F-FDG PET/CT相比,18F-PSMA 1007 PET/CT在原发右肾肿瘤显示强烈示踪剂浓聚。
- 18F-PSMA 1007 PET/CT在所有肺结节均一致显示强烈示踪剂浓聚。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 60-year-old man with suspected right renal cell carcinoma underwent F-FDG PET/CT and F prostate-specific membrane antigen (PSMA) 1007 PET/CT scan. Compared with the F-FDG PET/CT scan, F-PSMA 1007 PET/CT showed intense tracer concentration in the primary tumor in the right kidney and intense tracer concentration consistently in all lung nodules. Unlike noted in previous pilot studies with Ga-PSMA, we observed that the primary renal tumor also showed intense tracer avidity with F-PSMA 1007. F-PSMA 1007 PET/CT may provide preoperative insight into possible etiology, histopathological probability of tumor type, staging information, and theranostic potentials in evaluation of suspected renal cell carcinoma.
引用
- Marafi F, Sasikumar A, Al-Terki A, et al. 18F-PSMA 1007 in Suspected Renal Cell Carcinoma. Clin Nucl Med. 2020. PMID: 32209880. doi:10.1097/RLU.0000000000003002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。